Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD

Jump to Section1. Introduction2. Methods  2.1. Sample characteristics  2.2. Cognitive outcome: The PACC  2.3. Clinical progression outcomes: Diagnosis of MCI or AD dementia and Clinical Dementia Rating  2.4. PET data acquisition and analysis  2.5. Statistical analyses3. Results  3.1. Demographic characteristics  3.2. Cognitive decline by Aβ+ status and cohort  3.3. Clinical progression by Aβ+ status and cohort  3.4. Cognitive decline and subsequent clinical disease progression    3.4.1. Progression to MCI/dementia (model 1)    3.4.2. Progression to CDR>0 (model 2)    3.4.3. Concurrent cognitive decline and functional progression (model 3)  3.5. Further analysis of the association between cognition and MCI diagnosis in the HABS4. Discussion  4.1. Limitations5. ConclusionsSupplementary dataReferences

Read more…